| Title | Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma. | | Author(s) | Ozkurt ZN, Sucak GT, Akı SZ, Yağcı M, Erdem O | | Institution | Hematology Department, Gazi University Faculty of Medicine, Ankara, Turkey. | | Source | Cutan Ocul Toxicol 2009; 28(3):141-143. | | Abstract | Bortezomib is a potent, selective proteasome inhibitor. It is usually well tolerated, and bortezomib-induced skin lesions are less well known. A 59-year-old man with multiple myeloma underwent autologous hematopoetic stem cell transplantation (AHSCT). Administration of bortezomib was started after AHSCT as his disease progressed despite thalidomide maintenance. He developed a rash afer the third cycle of bortezomib. A biopsy showed superficial and deep perivascular dermatitis. The rash resolved within 4 days; complete response of myeloma was obtained after 8 cycles of bortezomib. The benign clinical course did not require interruption of the treatment, which in turn resulted in complete remission of myeloma. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19548772 |
|
